DB:1UC

Stock Analysis Report

Executive Summary

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.

Rewards

Revenue is forecast to grow 46.17% per year

Risk Analysis

Earnings have declined by -51.57% per year over past 5 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Cue Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1UC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

1UC

-8.1%

DE Biotechs

0.07%

DE Market


1 Year Return

105.7%

1UC

5.9%

DE Biotechs

14.8%

DE Market

Return vs Industry: 1UC exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: 1UC exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

1UCIndustryMarket
7 Day0%-8.1%0.07%
30 Day0%-3.4%1.4%
90 Day74.4%12.2%6.1%
1 Year105.7%105.7%6.1%5.9%18.4%14.8%
3 Yearn/a56.9%55.1%17.4%7.0%
5 Yearn/a16.4%13.9%27.9%10.4%

Price Volatility Vs. Market

How volatile is Cue Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cue Biopharma undervalued compared to its fair value and its price relative to the market?

13.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1UC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1UC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1UC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1UC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1UC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1UC is overvalued based on its PB Ratio (13.4x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Cue Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

46.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1UC's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if 1UC's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1UC's revenue (46.2% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 1UC's revenue (46.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1UC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cue Biopharma performed over the past 5 years?

-51.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1UC is currently unprofitable.

Growing Profit Margin: 1UC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1UC is unprofitable, and losses have increased over the past 5 years at a rate of -51.6% per year.

Accelerating Growth: Unable to compare 1UC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1UC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 1UC has a negative Return on Equity (-145.82%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cue Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: 1UC's short term assets ($33.0M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: 1UC's short term assets ($33.0M) exceed its long term liabilities ($7.8M).


Debt to Equity History and Analysis

Debt Level: 1UC is debt free.

Reducing Debt: 1UC has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 1UC has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1UC's debt is not covered by short term assets (assets are -3.7143437926738E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1UC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1UC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -44.1% each year


Next Steps

Dividend

What is Cue Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1UC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1UC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1UC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1UC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1UC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Cue Biopharma's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Dan Passeri (58yo)

3.4yrs

Tenure

US$833,858

Compensation

Mr. Daniel R. Passeri, also known as Dan, MSc., J.D. has been the Chief Executive Officer of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until October 3, 2019.  ...


CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD833.86K) is about average for companies of similar size in the German market ($USD817.80K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.9yrs

Average Tenure

54yo

Average Age

Experienced Management: 1UC's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Age and Tenure

3.9yrs

Average Tenure

58yo

Average Age

Experienced Board: 1UC's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: 1UC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Sell€358,40831 Dec 19
Christopher Marlett
EntityIndividual
Shares24,700
Max Price€15.36
Sell€567,82127 Dec 19
Christopher Marlett
EntityIndividual
Shares36,647
Max Price€15.79
Sell€354,34819 Dec 19
Christopher Marlett
EntityIndividual
Shares24,732
Max Price€15.28
Buy€8,82925 Jun 19
Daniel Passeri
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,377
Max Price€6.41
Buy€117,27010 Jun 19
Colin Sandercock
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares16,938
Max Price€7.01
Buy€18,33007 Jun 19
Daniel Passeri
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares3,000
Max Price€6.11

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.


Management Team

  • Dan Passeri (58yo)

    CEO & Director

    • Tenure: 3.4yrs
    • Compensation: US$833.86k
  • Colin Sandercock (62yo)

    Senior VP

    • Tenure: 2.1yrs
    • Compensation: US$330.22k
  • Ken Pienta (59yo)

    Acting Chief Medical Officer

    • Tenure: 2.8yrs
  • Ron Seidel (43yo)

    Executive VP and Head of Research & Development

    • Compensation: US$316.63k
  • Rodolfo Chaparro (46yo)

    Executive VP & Head of Immunology

    • Compensation: US$316.63k
  • Steven Almo (58yo)

    Co-Founder and Chairman of Scientific & Clinical Advisory Board

    • Tenure: 5yrs
  • Anish Suri (46yo)

    President & Chief Scientific Officer

    • Tenure: 0.3yrs
    • Compensation: US$3.33m
  • Kerri-Ann Millar (50yo)

    VP of Finance and Principal Accounting & Finance Officer

    • Tenure: 1.7yrs
  • Brandan Hillerich

    Vice President of Corporate Development & Strategy

    • Tenure: 1.5yrs

Board Members

  • Steven McKnight (70yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$129.35k
  • Fred Driscoll (68yo)

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$518.83k
  • Dan Passeri (58yo)

    CEO & Director

    • Tenure: 3.4yrs
    • Compensation: US$833.86k
  • Peter Kiener (67yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$173.42k
  • Barry Simon (54yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: US$140.85k
  • David Baker

    Member of Scientific & Clinical Advisory Board

    • Hidde Ploegh

      Member of Scientific & Clinical Advisory Board

      • Cameron Gray (48yo)

        Director

        • Tenure: 5yrs
        • Compensation: US$96.60k
      • Christopher Marlett (54yo)

        Director

        • Tenure: 4.6yrs
        • Compensation: US$96.60k
      • Steven Almo (58yo)

        Co-Founder and Chairman of Scientific & Clinical Advisory Board

        • Tenure: 5yrs

      Company Information

      Cue Biopharma, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: Cue Biopharma, Inc.
      • Ticker: 1UC
      • Exchange: DB
      • Founded: 2014
      • Industry: Biotechnology
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$354.110m
      • Listing Market Cap: US$319.230m
      • Shares outstanding: 22.99m
      • Website: https://www.cuebiopharma.com

      Number of Employees


      Location

      • Cue Biopharma, Inc.
      • 21 Erie Street
      • Cambridge
      • Massachusetts
      • 2139
      • United States

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      CUENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2018
      1UCDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2018

      Biography

      Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/19 22:15
      End of Day Share Price2019/12/13 00:00
      Earnings2019/09/30
      Annual Earnings2018/12/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.